TRT and Cardiovascular Risk: The TRAVERSE Trial Results
Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS
The TRAVERSE trial, a large-scale, randomized, placebo-controlled study, investigated the cardiovascular safety of testosterone replacement therapy in men with hypogonadism and pre-existing cardiovascular disease or risk factors. Its findings indicated that TRT was non-inferior to placebo regarding major adverse cardiovascular events (MACE), providing crucial evidence for the cardiovascular safety profile of testosterone therapy when appropriately prescribed and monitored.
TRT and Cardiovascular Risk: The TRAVERSE Trial Results
The relationship between Testosterone Replacement Therapy (TRT) and cardiovascular (CV) risk has long been debated. Conflicting early studies led to caution in prescribing TRT, especially for men with pre-existing CV disease. The large, randomized, placebo-controlled TRAVERSE trial was designed to definitively address these safety concerns, reshaping clinical understanding [1].
TRAVERSE Trial Methodology: A Rigorous Assessment
The TRAVERSE trial enrolled 5,246 hypogonadal men (testosterone <300 ng/dL) aged 45-80 with pre-existing or high-risk CV disease. Participants received topical testosterone gel or placebo. The primary safety endpoint was a composite of major adverse cardiovascular events (MACE): non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death. Mean follow-up was 33 months [2, 3].
Key Findings: Reassuring Cardiovascular Safety
TRAVERSE delivered a clear message on TRT's cardiovascular safety:
- Non-inferiority to Placebo: TRT was non-inferior to placebo for MACE, meaning it did not increase major adverse cardiovascular events in hypogonadal men with pre-existing or high CV risk [2, 4].
- No Increase in MACE: MACE incidence (non-fatal MI, non-fatal stroke, CV death) was not significantly higher in the testosterone group (hazard ratio 0.96; 95% CI, 0.78 to 1.17), indicating no increased risk [2].
- Other Adverse Events: The trial observed higher incidences of atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone group, emphasizing careful patient selection and monitoring [2].
- Informed Decision-Making: Clinicians can now have more informed discussions with patients about TRT benefits for hypogonadal symptoms (e.g., improved libido, mood, energy) without undue MACE risk concerns.
- Patient Selection and Monitoring: Despite overall CV safety, increased atrial fibrillation, acute kidney injury, and pulmonary embolism necessitate careful patient selection, baseline evaluation, and ongoing monitoring during TRT [2].
- Addressing Previous Concerns: TRAVERSE directly addresses earlier studies (e.g., 2010 T-Trial) that suggested a TRT-CV event link, providing a more definitive answer with its large size and rigorous design.
These results align with recent meta-analyses suggesting no increased CV risk with appropriate TRT use [5].
Clinical Implications: Reshaping TRT Prescribing Practices
TRAVERSE provides strong evidence for TRT's cardiovascular safety in high-risk populations, increasing clinician confidence in prescribing testosterone for symptomatic hypogonadism with CV concerns. This marks a significant shift from previous anxieties.
TRAVERSE vs. Earlier Studies: A Paradigm Shift
| Aspect | TRAVERSE Trial (2023) | Earlier Studies (e.g., T-Trial, observational) |
| :--------------------- | :--------------------------------------------------------------- | :------------------------------------------------------------------- |
| Design | Large, randomized, placebo-controlled, non-inferiority | Smaller, observational, or less rigorous designs |
| Population | Hypogonadal men with pre-existing CV disease or high CV risk | Varied, sometimes included men without confirmed hypogonadism |
| Primary CV Outcome | Non-inferiority for MACE (non-fatal MI, non-fatal stroke, CV death) | Conflicting, some suggested increased CV risk |
| Key Finding | TRT was non-inferior to placebo for MACE | Raised concerns about potential increased CV risk |
| Clinical Impact | Increased confidence in TRT CV safety, improved prescribing guidance | Led to caution and reluctance in TRT prescribing |
Clinical Takeaway
The TRAVERSE trial robustly demonstrates that TRT does not increase major adverse cardiovascular events (MACE) in hypogonadal men with pre-existing or high CV risk. While reassuring for overall CV safety, vigilance for atrial fibrillation, acute kidney injury, and pulmonary embolism is crucial. These findings empower clinicians to prescribe TRT with greater confidence, emphasizing appropriate patient selection and monitoring.